Compare Ginkgo Bioworks Holdings Inc (DNA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Rocket Lab USA Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 57.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Rocket Lab USA Inc for 29 Days on average.
| DNA | RKLB | |
|---|---|---|
Market Cap | $763.64M | $43.74B |
Volume | 3,204,177 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $15.83 | $150.23 |
52-Week Low | $5.48 | $39.48 |
Typical Hold Time | 7 Days | 29 Days |
Enterprise Value | $865.59M | $41.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Rocket Lab (RKLB) trades at $68.40, down 4.89% today, amid bearish technical signals despite positive business developments. The company recently secured its largest-ever commercial Electron launch contract with Synspective for 20 missions, expanding its backlog to over 100 launches. Fundamentally, RKLB shows strong revenue growth with $602 million in 2025 and projected $769 million in 2026, though it remains unprofitable with negative margins. Analyst sentiment remains overwhelmingly bullish with 16 buy ratings and a $107 consensus price target, representing significant upside potential from current levels.
Rocket Lab presents a high-risk, high-reward opportunity with substantial growth potential in the expanding space economy offset by persistent losses and competitive threats from SpaceX. The company's expanding launch backlog and Neutron rocket development provide long-term catalysts, but investors must weigh the premium valuation against ongoing cash burn and execution risks in a capital-intensive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
